NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5459.50 34.50 (0.64%)

178.2K NSE+BSE Volume

NSE 01 Oct, 2025 3:31 PM (IST)

65,276.5

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Alkem Laboratories Ltd.

06 Apr 2017

5459.50

0.64%

Alkem Labs (Update): Take a breather. Downgrade to NEUTRAL

Neutral: Alkem Laboratories Ltd.

Recommendation Target

HDFC Securities

After the recent run-up, the stock is trading at 27.2x FY18E and 20.5x FY19E, a premium to mid-cap peers. We believe that the coming months will see some correction in the stock price and provide fresh entry points for investors to participate in ALKEM?s growth story again.

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

17 Feb 2017

5459.50

0.64%

Result Update:Alkem Lab

Buy: Alkem Laboratories Ltd.

Axis Direct

Q3 EBITDA was 19% higher than our estimate led by strong growth in key markets Domestic formulations (up 13.5% YoY vs. our est. 8%) and US (up 30% YoY vs our est. 16%) leading to gross margin expansion of 300 bps (both YoY/QoQ).

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

14 Feb 2017

5459.50

0.64%

Result Updates

Accumulate: Alkem Laboratories Ltd.

Recommendation Target

Angel Broking

The stock at the CMP of Rs1,837 is available at P/E of 17.5x of FY19E EPS of `105. The stock price in CY2017 has appreciated by 13% leaving less room for further upside at this juncture. We expect company to report CAGR of 17.4% and 22.4% in top line and bottom line respectively in next two years. Its ANDA pipeline has not seen strong tra..

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Alkem Laboratories Ltd.

11 Feb 2017

5459.50

0.64%

Alkem (3QFY17): Growth story continues. Maintain BUY

Buy: Alkem Laboratories Ltd.

Target

HDFC Securities

Alkem (ALKEM) reported strong numbers in 3QFY17 as the top-line grew by ~16% YoY, helped by a 13.5% growth in India (highest among peers) and ~30% YoY growth in the US (~8% beat). EBITDA margins at 18.1% and earnings growth of ~24%YoY were a positive surprise.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

03 Jan 2017

5459.50

0.64%

Alkem Laboratories Ltd

Buy: Alkem Laboratories Ltd.

Angel Broking

Alkem Laboratories is a Mumbai based pharma company engaged in manufacturing and marketing of generic drugs, APIs and neutraceutical products. Company sells its drugs in India and ~50 countries including the US. It has 16 manufacturing facilities of which 14 are in India and two in the USA. The stock at the CMP of Rs1,620 is available at ..

Alkem Laboratories Ltd. is trading above all available SMAs

Alkem Laboratories Ltd.

20 Oct 2016

5459.50

0.64%

Alkem (Initiating Coverage): Compounding story. BUY

Buy: Alkem Laboratories Ltd.

HDFC Securities

ALKEMs flourishing Indian acute business (65% of rev.) and growing US segment (24% CAGR) provide a strong foundation for another compounding story to unfold from Indian generics. In India, ALKEM has 15 acute brands in top 300 and is the 4th fastest growing company in the last five years. With US revenues likely to grow at a fast clip, ALKEM?s top line (18% CAGR) and profitability improvement ( 280bps) will drive 24% EPS CAGR over FY16-19E.

Alkem Laboratories L.. has an average target of 5463.50 from 2 brokers.

Is Alkem Laboratories Ltd. worth buying?

139 Votes:

Buy 79.14%

Sell 14.39%

Hold 6.47%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf